Form 4: STAAR Surgical Director Elizabeth Yeu Reports Stock and Options Grant

Director Elizabeth Yeu reported the acquisition of common stock and options in STAAR Surgical Co. on June 20, 2024, as part of the company's annual non-employee director equity compensation program.

Summary

• On June 20, 2024, Elizabeth Yeu, a director of STAAR Surgical Co., reported acquiring 2,244 shares of common stock and options for 4,010 shares of common stock.
• The transactions were part of the company's annual non-employee director equity compensation program for the 2024-2025 term.
• The restricted stock was acquired at $0.00 price.
• The options have an exercise price of $40.11 and expire on June 19, 2034.
• The equity awards vest fully on the earlier of June 20, 2025, or the Corporation's 2025 Annual Meeting of Shareholders.
• Following the reported transactions, Yeu beneficially owns 5,099 shares of common stock and 4,010 common stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard equity grant to a director, which is generally viewed as a positive sign of aligning interests with shareholders.

Positives

• The equity grant aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The equity awards vest in full on the earlier of June 20, 2025, or the Corporation's 2025 Annual Meeting of Shareholders, indicating a future event that will trigger the full ownership of these securities.

Industry Context

Equity compensation for non-employee directors is a common practice in publicly traded companies to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock and option grants, are typical in publicly traded companies like STAAR Surgical.
• Comparable companies such as Alcon, Johnson & Johnson, and Bausch Health also utilize equity-based compensation for their board members.
• The specific amounts and vesting schedules vary based on company size, performance, and industry benchmarks.

Stakeholder Impact

• Shareholders may view the equity grant as a positive sign of aligning director interests with long-term company performance.
• The director is incentivized to contribute to the company's success to increase the value of their equity holdings.

Next Steps

• The director will need to hold the stock and/or exercise the options according to the vesting schedule.
• The company will likely continue to grant equity compensation to directors in future years.

Key Dates